ArticleBioMed research international2026
Comprehensive Genotoxicity and 28-Day Oral Toxicity Evaluation Reveal Safety of a Standardized Anisomeles indica-Containing Powder.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive Genotoxicity and 28-Day Oral Toxicity Evaluation Reveal Safety of a Standardized Anisomeles indica-Containing Powder.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anisomeles indica is widely used in traditional medicine and functional foods; however, its toxicological safety has not been systematically evaluated. This study evaluated the genotoxicity and subacute oral toxicity of a standardized A. indica-containing powder (AIHP) using OECD-compliant test guidelines. Genotoxicity was assessed via the bacterial reverse mutation test (OECD 471), in vitro chromosomal aberration test (OECD 473), and in vivo micronucleus assay in mice (OECD 474). A repeated-dose 28-day oral toxicity study (OECD 407) was performed in Sprague-Dawley rats at doses of 2000, 4000, and 8000 mg/kg/day. AIHP did not induce mutagenicity, chromosomal aberrations, or micronucleus formation in any assay. No treatment-related mortality, clinical signs, or adverse changes in body weight, hematology, serum biochemistry, organ weights, urinalysis, or histopathology were observed. The no-observed-adverse-effect level (NOAEL) was established at 8000 mg/kg/day. These results support the toxicological safety of AIHP and its suitability for use as a health food ingredient.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.